Farnesylated Glycol Chitosan as a Platform for Drug Delivery: Synthesis, Characterization, and Investigation of Mucus-Particle Interactions

Biomacromolecules. 2018 Aug 13;19(8):3489-3501. doi: 10.1021/acs.biomac.8b00795. Epub 2018 Jul 23.

Abstract

Amphiphilic polymer-based drug delivery systems hold potential in enhancing pharmacokinetics and therapeutic efficacy due to their ability to simultaneously codeliver different drugs in a controlled manner. We propose here a facile method for synthesizing a new amphiphilic polymer, farnesylated glycol chitosan (FGC), which self-assembles into nanoparticles upon being dispersed in aqueous media. The characteristics of FGC nanoparticles, in particular the size, could be tuned in a range from 200 to 500 nm by modulating the degree of farnesylation and the pH and polymer concentration during particle preparation. Carrier capacity, release kinetics, and surface modification of the established system were investigated using different model compounds. The colloids were biocompatible and stable at biologically relevant pH values. The interactions between the carriers and human mucus were examined by multiple particle tracking, which revealed that ∼80% of the particles remain immobilized within the mucus matrix. These results postulate FGC as a versatile drug delivery platform.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Chitosan / analogs & derivatives*
  • Glycols / chemistry
  • Humans
  • Nanoparticles / adverse effects
  • Nanoparticles / chemistry*
  • Prenylation
  • Respiratory Mucosa / drug effects*
  • Respiratory Mucosa / metabolism

Substances

  • Glycols
  • Chitosan